Acorda Therapeutics (ACOR) Tops Q2 EPS by 27c
Get Alerts ACOR Hot Sheet
Price: $0.66 --0%
EPS Growth %: -139.7%
Financial Fact:
License and royalty revenue: 2.26M
Today's EPS Names:
NLY, CP, RUSHA, More
EPS Growth %: -139.7%
Financial Fact:
License and royalty revenue: 2.26M
Today's EPS Names:
NLY, CP, RUSHA, More
Join SI Premium – FREE
Acorda Therapeutics (NASDAQ: ACOR) reported Q2 EPS of $0.42, $0.27 better than the analyst estimate of $0.15. Revenue for the quarter came in at $97.13 million versus the consensus estimate of $91.4 million.
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ford (F) earnings top estimates in Q1 amid strength in Pro unit; stock up
- VIST Financial Corp. (VIST) Misses Q1 EPS by 19c
- ESSA Bancorp (ESSA) Tops Q2 EPS by 13c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!